Purple Biotech (PPBT) Enterprise Value (2014 - 2026)
Purple Biotech (PPBT) posted quarterly Enterprise Value of -$6.5 million for Q1 2026, up 1.31% year-over-year from -$6.4 million in Q1 2025, and up 32.66% quarter-over-quarter from -$9.6 million in Q4 2025.
Purple Biotech (PPBT) Enterprise Value (2014 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Enterprise Value for 13 consecutive years, with -$6.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value rose 1.31% year-over-year to -$6.5 million; the TTM figure through Mar 2026 stood at -$6.5 million (up 1.31% YoY), while the FY2025 annual figure was -$9.6 million, down 26.28% from the prior year.
- Enterprise Value rose to -$6.5 million in Q1 2026 per PPBT's latest filing, from -$9.6 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$5.5 million in Q2 2025 and bottomed at -$39.3 million in Q1 2022.
- Historically, Enterprise Value has averaged -$15.6 million across 5 years, with a median of -$10.8 million in 2024.
- Annual changes were most pronounced in 2022 — Enterprise Value surged 67.45% — and 2025, when it plunged 67.13%.
- Purple Biotech's Enterprise Value stood at -$15.3 million in 2022, then climbed by 0.16% to -$15.2 million in 2023, then jumped by 50.0% to -$7.6 million in 2024, then slipped by 26.28% to -$9.6 million in 2025, then soared by 32.66% to -$6.5 million in 2026.
- Business Quant data shows PPBT's Enterprise Value at -$6.5 million in Q1 2026, -$9.6 million in Q4 2025, and -$10.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.69 Bn | 130.84 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.29 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 64.79 Bn | 59.60 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 59.44 Bn | 54.31 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.07 Bn | 36.97 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 30.92 Bn | 27.61 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 28.10 Bn | 9.71 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.33 Bn | 26.17 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - | 2.12 Bn |
| 10 | Purple Biotech | 127.07 | 127.07 | - | -6.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.48 Mn |
| Dec 31, 2025 | -9.63 Mn |
| Sep 30, 2025 | -10.41 Mn |
| Jun 30, 2025 | -5.55 Mn |
| Mar 31, 2025 | -6.57 Mn |
| Dec 31, 2024 | -7.63 Mn |
| Sep 30, 2024 | -6.23 Mn |
| Jun 30, 2024 | -7.31 Mn |
| Mar 31, 2024 | -10.76 Mn |
| Dec 31, 2023 | -15.25 Mn |
| Sep 30, 2023 | -15.83 Mn |
| Jun 30, 2023 | -17.91 Mn |
| Mar 31, 2023 | -22.57 Mn |
| Dec 31, 2022 | -15.27 Mn |
| Sep 30, 2022 | -32.87 Mn |
| Jun 30, 2022 | -35.77 Mn |
| Mar 31, 2022 | -39.29 Mn |
| Dec 31, 2021 | -46.92 Mn |
| Sep 30, 2021 | -45.25 Mn |
| Jun 30, 2021 | -48.06 Mn |